Conference
Outcomes of advanced urothelial carcinoma following discontinuation of programmed death (PD)-1 or PD-ligand (L)-1 inhibitors.
Abstract
385
Background: The outcomes and therapy of advanced urothelial carcinoma (UC) patients (pts) following discontinuation of PD-1/PD-L1 inhibitors are unclear. We performed a retrospective analysis to examine the frequency of systemic therapy administered following PD-1/PD-L-1 inhibitors and outcomes in these pts. Methods: Data were collected from institutions for pts with advanced UC following prior PD-1/PD-L1 inhibitors as …
Authors
Sonpavde G; Pond GR; Mullane SA; Ramirez AA; Vogelzang NJ; Necchi A; Powles T; Bellmunt J
Volume
34
Pagination
pp. 385-385
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
January 10, 2016
DOI
10.1200/jco.2016.34.2_suppl.385
Conference proceedings
Journal of Clinical Oncology
Issue
2_suppl
ISSN
0732-183X